Nyxoah Raises $27 Million Through Its At-the-Market Offering

PRIOR INFORMATION
REGULATED INFORMATION

Nyxoah raises $27 million through its At-the-Market offering

Investment by a new US healthcare investor, strengthening the balance sheet and strengthening the US focus

Mont-Saint-Guibert, Belgium – October 7, 2024, 11:00 PM CET / 5:00 PM ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company developing breakthrough treatment alternatives for obstructive sleep apnea (OSA) through neuromodulation, today announced that the company has sold 3.0 million shares , which raised $27.0 million in gross proceeds pursuant to the Company’s $50 million at-the-market (“ATM”) offering at a price per share equal to the market price on the Nasdaq Global Market at the time. of sale. The shares were sold based on the interest received to a single US healthcare investor. Cantor Fitzgerald & Co. is acting as sales agent for the ATM offering.

The shares of common stock described above were sold by the Company pursuant to the Company’s registration statement on Form F-3 (File No. 333-268955) filed with the Securities and Exchange Commission (“SEC”) on December 22, 2022, which became effective on January 6, 2023 and included a prospectus supplement and accompanying prospectus relating to the ATM offering. Copies of the prospectus supplement and accompanying prospectus relating to the ATM offering may be obtained from Cantor Fitzgerald & Co., Attention: Capital Markets. , 110 East 59th Street, 6th Floor, New York, New York 10022; email: [email protected]. Electronic copies of the prospectus are also available on the SEC’s website at http://www.sec.gov.

Olivier Taelman, Chief Executive Officer of Nyxoah, commented: “After moving to the United States with my family last summer, this investment reinforces our focus on the United States and builds on our compelling DREAM pivotal research data presented at the International Surgical Sleep Society (ISSS) conference and strengthens our financial position, providing additional opportunities as we prepare to launch Genio® in the United States.”

About Nyxoah
Nyxoah reinvents sleep for the billion people suffering from obstructive sleep apnea (OSA). We are a medical technology company developing groundbreaking treatment alternatives for OSA through neuromodulation. Our first innovation is Genio®, a battery-free hypoglossal neuromodulation device that is inserted through a single incision under the chin and controlled by a wearable device. Through our commitment to innovation and clinical evidence, we have demonstrated best-in-class results for reducing the burden of OSA.

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following positive results from the BETTER SLEEP trial, Nyxoah received CE Mark for expanding its therapeutic indications to Complete Concentric Collapse (CCC) patients , which are currently contraindicated in competitor therapy. In addition, the company announced positive results from the pivotal DREAM IDE study for FDA and US commercialization approval.

Caution – CE marked since 2019. Research device in the United States. Restricted by US federal law to research use in the United States.

FORWARD-LOOKING STATEMENTS

Certain statements, beliefs and opinions contained in this press release are forward-looking and reflect the current expectations of the Company or, as applicable, the Company’s directors or management with respect to the Genio® System; planned and ongoing clinical trials of the Genio® System; the potential benefits of the Genio® system; Nyxoah’s objectives regarding the development, regulatory pathway and potential use of the Genio® System; the usefulness of clinical data in potentially obtaining FDA approval for the Genio® System; and reporting data from Nyxoah’s pivotal DREAM US study; receipt of FDA approval; access to the US market; and the expected closing and use of proceeds from the offering. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial consequences of the plans and events described herein. In addition, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2023 filed with the Securities. and Exchange Commission (“SEC”) on March 20, 2024, and subsequent reports the Company files with the SEC. A variety of factors, including but not limited to changes in demand, competition and technology, could cause actual events, performance or results to differ materially from those anticipated. Forward-looking statements in this press release regarding past trends or activities are not guarantees of future performance and should not be construed as a representation that such trends or activities will continue in the future. Furthermore, even if actual results or developments are consistent with the forward-looking statements in this press release, these results or developments may not be indicative of results or developments in future periods. No representations or warranties are made as to the accuracy or fairness of such forward-looking statements. Accordingly, the company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements contained in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which such forward-looking statements are based , unless specifically required by law or regulation. Neither the Company, its advisors or representatives, nor any of its affiliates or the officers or employees of any such person warrants that the assumptions underlying such forward-looking statements will be free from errors nor accept any responsibility for their future accuracy of the forward-looking statements. statements in this press release or the actual occurrence of the predicted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities in the offering nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration. or qualification under the securities laws of any such jurisdiction.

Contacts:

Nyxoah
Loïc Moreau, financial director
[email protected]

For media
In the United States
FINN Partners – Glenn Silver
[email protected]

In Belgium/France
Backstage communication – Gunther De Backer
[email protected]

In International/Germany
MC Services – Anne Hennecke
[email protected]